A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futile.
The KeyVibe-010 study was looking at a co-formulation of experimental vibostolimab and pembrolizumab – the active ingredient in MSD’s Keytruda – as an adjuvant treatment for patients with high-risk melanoma treated with surgery.
